Inhalational Bacteriophage and Nanosilver Effectiveness on nCOVID-19: A Case Report

Abstract

This is a case report of an immunocompromised plus (nCOVID-19) infected elderly Iraqi man in the AL-KARAMA respiratory care unit. Consequently, this man presented on 2/6/2020 following accelerated respiratory deterioration over two days with positive PCR and CT scan confirmation. Ordinarily, SPO2 84% at room temp despite the oxygen administration 4 L/min, not intubated. Therefore, the physician staged this case as IIb according to clinical staging for nCOVID-19. Moreover, he had uncontrolled IDDM and right nephrectomy for renal cell carcinoma before three years. Although, the physician applied nCOVID-19 guidelines of the ministry of Health-Iraq for three days but without a response. So, the researchers added an Inhalational Bacteriophage solution to an Inhalational Nanosilver colloid (designated by the authors) alternative after patient consent. Interestingly, there were fast and notable improvements in the patient's overall health plus relief of the respiratory symptoms. Consequently, a continuous increase in his SPO2 over the next day approaching 97%. Moreover, an improvement in his speaking and walking commencing to discharge well plus a negative PCR. Thus, the Inhalational Bacteriophage and Nanosilver are the most beneficial treatment including the prevention of nCOVID-19 complications in all stages